StemCell Therapy

BILLERICA, Mass.--(BUSINESS WIRE)--Powering Precision Health (PPH), the internationally acclaimed Summit focused on precision health and the latest in biomarker research, drew record attendance at its fourth-annual event held Nov. 19 in Barcelona, Spain, convening the worlds foremost scientists and medical leaders in precision health to introduce novel and disruptive research across the fields of neurology and oncology.

The PPH Summit continues to evolve and grow as the global epicenter for transforming healthcare with the use of non-invasive biochemical biomarkers, and this years event was no exception, said Kevin Hrusovsky, PPH Founder. PPH Summit is a unique opportunity to collaborate on the many seminal advances in measuring biomarkers minimally invasively, understanding their role in health, personalized treatment and disease prevention from a global community of scientific leaders. The research around blood-based biomarkers is gaining significant traction in the healthcare industry. The 2019 Summit offered us the chance to discuss and debate credible advances toward the clinic in drug development utilizing biomarkers and the mounting body of evidence these breakthroughs are advancing in preventative medicine around the world. We are excited to see so many of todays leading medical innovators, investors and patient advocates focused on utilizing disruptive biomarker technologies to advance the science that powers precision health.

Hrusovsky kicked off the Summit with a talk entitled, Vision to Reality: Disrupting Healthcare with Digital Biomarkers, highlighting the growing clinical evidence for neurofilament light (Nf-L) as a blood biomarker for detecting, prognosing and monitoring neurodegenerative conditions, and driving new biomarker research breakthroughs in oncology and immuno-oncology. The attendees were energized for an important day of discussions, tackling high-priority disease areas such as cancer and neurodegeneration with blood-based biomarkers as evidenced by the more than 40 research presentations shared at the event alone. There are now over 650 third-party peer-reviewed publications highlighting disruptive biomarker technologies for early disease detection, drug development and disease prevention.

Attendees were also treated to a fireside chat-style Q&A, Fraud is Not a Trade Secret, with Tyler Shultz, CEO of Flux Biosciences, Inc., widely known as the Theranos whistleblower, which highlighted the importance of PPHs impact on restoring transparency and investor trust. Hosted by Nasdaq Spotlight correspondent Lyanne Alfaro, Shultz and Hrusovsky discussed the importance of ethics, accountability and nurturing a culture of transparency and open debate in medical innovation and entrepreneurship.

Highlights from PPH 2019 Neurology Track include research presentations further revealing the advantages of Quanterix Simoa technology in enabling sensitive detection of important biomarkers in many neurological diseases. In particular, several talks highlighted the role of Nf-L as a promising diagnosis and treatment monitoring biomarker in Multiple Sclerosis (MS), and suggested that it is getting close to becoming a clinically relevant tool. Nf-L was also reported as a promising biomarker for several other neurodegenerative diseases such as traumatic brain injury (TBI), frontotemporal dementia (FTD), Parkinsons disease, ALS, Huntington disease and peripheral neuropathies. In one of the presentations, new data revealed that Nf-L levels were elevated in mutation carriers several years prior to clinical symptoms of Huntington disease, observations similar to those published earlier for ALS, AD, FTD and MS. The collective data suggests that Nf-L may become a screening tool for people at risk for developing neurodegenerative diseases earlier, and will in turn facilitate clinical trials, and eventually a better chance for people suffering from those diseases, to be treated earlier and more successfully. Additionally, new data was also presented on phosphorylated tau and its potential to aid in detection of amyloid pathologies when used in combination with other biomarkers, such as amyloid beta isoforms 40 and 42. Many PPH speakers continuously emphasized the importance of panels of biomarkers that allow identification of specific disease mechanisms and endophenotypes in the future.

Andrew Beard, Head of Business Development and Companion Diagnostics, Molecular Services US at Siemens Healthineers, talked about the transition of a biomarker from research to clinical use. He also described the importance of combining imaging with molecular measurements, including Nf-L. Beard described development of the Nf-L assay on the automated immunoanalyzer to support future global use of Nf-L in clinic.

The PPH 2019 Oncology Track featured research extolling the benefits of ultra-sensitive immunoassays for biomarker analysis in clinical samples, as well as analytical and diagnostic validation of single and multiplex protein biomarkers for the detection of cancer. The expert panel discussion, Applying Digital Protein Biomarkers to Oncology & Immuno-Oncology: Is the Time Now? addressed the critical nature of using fit for purpose validated biomarkers to advance drug discovery and development efforts for anti-angiogenesis inhibitors, immuno-oncology and other key inflammatory applications, breast cancer, and how to choose and implement relevant biomarkers in clinical practice.

PPH is about collaboration; its what we can learn from each other. Thats going to get us answers much faster than working independently, continued Hrusovsky. Scientific breakthroughs shared at this years event are creating a groundswell of new opportunities for seeing disease earlier in the cascade and long before symptoms present and hopefully leading to new strategies for drug development, therapy response and prevention.

The PPH 2019 Summit was made possible thanks to the generosity of multiple sponsors who embraced the vision of precision health, including: Biogen, Novartis, BTIG, Quanterix, Canaccord Genuity, Cowen Group, C2N, Adx NeuroSciences, Leerink, JP Morgan, Avison Young, Mintz Levin and Octave BioSciences.

Presentations are available for viewing here and in addition, watch the panel discussion on Challenges and Opportunities for Blood Tests for Alzheimers, MS, Parkinsons, and ALS, featuring several of todays leading scientific minds hailing from the University Hospital of Basel, the University of Gothenburg, Memorial Healthcare and the Michael J. Fox Foundation. To learn more about the PPH Summit, visit: https://poweringprecisionhealth.org.

About Powering Precision HealthPowering Precision Health is the world's first independent, non-profit organization dedicated to bringing the world's leading physicians, scientists, innovators, investors and patient advocates together to unveil their latest research on new biomarkers that are revolutionizing precision health. Founded by Kevin Hrusovsky, a widely acclaimed thought leader and visionary in life sciences and personalized medicine, Powering Precision Health is a movement that represents the intersection of new technological capabilities with the latest medical research. Its rooted in the science of precision medicine, which shows personalized treatments to be an increasingly more effective way to maximize drug efficacy and minimize toxicity. In addition to the impact environmental and lifestyle factors can have on minimizing disease triggers, precision health marks an evolution in the way we approach disease and aims to inspire a full healthcare transformation, from philosophy to approach to outcome. In an industry often plagued by skepticism and marred by false promises, PPH puts science first and brings together stakeholders that span from fundamental research to clinical practice, investors, policy makers, patient advocacy groups, and anyone who embraces the vision of Powering Precision Health. Featuring a distinguished keynote lineup of dignitaries, the Summit unveils groundbreaking approaches to prevention, early diagnosis, and next-generation treatments. Powering Precision Health is supported thanks to the generous contributions of sponsors from a wide range of companies and organizations committed to advancing precision health.

Twitter:@KevinHrusovsky @PPHSUMMIT

Facebook:@PoweringPrecisionHealth

LinkedIn:@PoweringPrecisionHealth

The rest is here:
Powering Precision Health Summit Convenes the World's Most Renowned Scientific Innovators Advancing Biomarker Technologies - Business Wire

We all know that high blood pressure increases the risk of coronary artery disease and stroke but rarely is information presented on the risks of low blood pressure. A number of medical studies have claimed little or no serious medical risk associated with low blood pressure with serious medical risk only being defined as a heart attack and stroke. Other medical studies suggest that low blood pressure does increase the risk of coronary artery disease, falling and even increases the risk of dementia and Alzheimer's disease. In both traditional and on-traditional medicine, low blood pressure is usually ignored even if there are clinical findings of the blood pressure being too low.

The medical risks of chronic high blood pressure are now well defined. But it was not always the case. At the turn of the century, high blood pressure was so common in the elderly that it was considered the natural result of aging. The famous Framingham Heart Study (1949-1952) showed that those with a systolic blood pressure over 159 had a three to six times increased of heart disease. Since then the relationship between high blood pressure and illnesses has been clearly delineated. As a result, many medications are available to lower high blood pressure are available and numerous lives saved.

Low blood pressure is not uncommon but with the increasing use of medications, not limited to blood pressure medications, low blood pressure has become a relatively common. Besides high blood pressure medications, drugs often used for Parkinson's disease, depression/anxiety, sedative-hypnotics, pain medications and muscle relaxants all can cause low blood pressure. This effect can be intensified when specific medications are used in combination.

There is limited clinical research on low blood pressure but two recent medical studies are pertinent today. One large study in the American Journal of Preventative Medicine looked at the risk of falls and loss of consciousness in almost one half a million people with low blood pressure. The concluded that a systolic blood pressure less than 110 significantly increased the risk of serious falls and loss of consciousness.

Another study in the Indian Heart Journal found that there is an increased risk of atrial fibrillation in people who had a history of dizziness with standing (serious low blood pressure). Atrial fibrillation is an irregular heartbeat that increases the risk of blood clots, stroke and heart failure. It most commonly occurs in the elderly as does low blood pressure. Interestingly high blood pressure is also a risk factor for atrial fibrillation. In this study low blood pressure also increased the risk of stroke and a 50 to 100 percent increased mortality rate probably secondary to a higher incidence of coronary heart disease and heart failure.

Traditional therapy for low blood pressure includes graded exercise, generous salt intake and caution going from sitting/laying to standing. I have found that a critical review of a patient's medications, select herbs and regular meditation can be curative. Low blood pressure should be taken as seriously as high blood pressure.

Dr. Patrick Massey, M.D., Ph.D., is medical director of complementary and alternative medicine at Alexian Brothers Hospital Network, and president of ALT-MED Medical and Physical Therapy, 1544 Nerge Road, Elk Grove Village.

Follow this link:
Low blood pressure is a risk and should be taken seriously - Chicago Daily Herald

Women have more control over their healthcare journeys when they can access preventative services, and have opportunities to detect and treat adverse conditions early."

ASHEVILLE, N.C. (PRWEB) December 12, 2019

Aeroflow Healthcare, a leading durable medical equipment (DME) provider and Inc. 5000 fastest growing company, and its executive leadership announced their continued support and public advocacy for female and mother/baby health rights via the Affordable Healthcare Act.

Aeroflow emphasizes the ACAs purpose of protecting many groups, including women, and under it, making preventative health services accessible for women with no cost-sharing meaning complete insurance coverage. These services include mammograms, cervical cancer screenings, prenatal care, and breastfeeding supplies, support and services, among many others.

It is Aeroflow Healthcares position that preventative healthcare is of utmost importance for the women in our lives, not only for their own livelihood, but for that of the children they bear and are often the primary caregiver and guardian of. U.S. healthcare is littered with statistics highlighting a much higher than expected infant mortality rate and an unacceptable number of complications and health scares both pre- and post-childbirth. The protection of the ACA should be reflective of the overwhelming support for legislature that provides preventative medicine and additional womens and family rights, ultimately saving patients and providers money.

Aeroflow stands in staunch support of the rights and welfare of expectant mothers, families, and women and men responsible for the guardianship of children, said Amanda Baethke, Director of Corporate Development. Women have more control over their healthcare journeys when they can access preventative services, and have opportunities to detect and treat adverse conditions early. As the ACA makes provisions for these services, we stand with the majority of American citizens who seek to protect it, and encourage the public to contact your representative in congress and tell them that the women in your life are far too important to lose healthcare options.

About Aeroflow Healthcare

Aeroflow Healthcare was founded Asheville, NC in 2001 as a home oxygen provider, and has since grown to become one of the leading durable medical equipment providers nationwide. For three consecutive years, Aeroflow has been ranked on Inc. Magazines List of 5000 Fastest Growing Companies. In 2017, Aeroflow was also awarded the HME Excellence Award for Best Home Medical Equipment Provider and has been recognized as a business offering top-notch benefits to employees with the Great Place to Work Award. Aeroflow is an accredited Medicare and Medicaid provider and accepts most commercial insurance. To learn more about Aeroflow Healthcare and getting medical equipment through insurance, visit http://www.Aeroflowinc.com.

Share article on social media or email:

See the original post here:
Aeroflow Healthcare: In Defense of the ACA, and Women and Family Healthcare Rights - PR Web

Such conservative bromides ignore the evidence that SNAP beneficiaries by and large do not want to depend on government difficult circumstances in their lives make it necessary and that the program does not dissuade them from working. Depriving them of assistance will only exacerbate their poverty, and cost Americans in other ways.

The policy change, effective April 1, will oust nearly 700,000 people from food stamps nationwide and cut $5.5 billion in SNAP spending over five years. Approximately 35,000 of those affected live in Massachusetts. They are underemployed adults who have no children and are not disabled generally, a group of people not eligible for the benefit. But a longstanding waiver program has allowed the Commonwealth and other states to enroll such people in SNAP for more than three months in a three-year period if they live in localities with high unemployment or a tight job market. A recent study revealed that nationwide this group of childless individuals has received an average of $181 every month in SNAP benefits due to the state waivers.

The new rule will impose stricter criteria for issuing the state waivers. The government wants to move more able-bodied SNAP beneficiaries toward self-sufficiency and into employment. These waivers have long been seen a weakness of the program a loophole exploited by low-income individuals who simply dont want to work at a time when there are 7 million job openings nationwide and the unemployment rate is at 3.6 percent.

But, the Trump Administration is ignoring . . . the connection between geography and employment opportunities, said Georgia Katsoulomitis, executive director of the Massachusetts Law Reform Institute, in a statement. "For example, this rule will disproportionately harm communities of color that are already struggling with economic instability and limited employment opportunities resulting from decades of explicit and implicit labor and housing discrimination.

Requiring some recipients of SNAP benefits to work more is a dramatic change from longstanding policy, one that Congress itself rejected twice last year when it was proposed in Trumps budget and in the farm bill the latter by a bipartisan House vote of 330-83. The new rule also rests on a grave misconception about the food assistance program: SNAP is intended to address hunger and help people rise out of poverty, not to compel them to work.

Indeed, there is no evidence that the new SNAP rule will result in more people gaining steady jobs. Instead, research has shown that nondisabled, low-income individuals face a complex set of barriers to self-sufficiency that have nothing to do with whether they get food stamps. Some cycle in and out of low-paying jobs or can only get irregular hours, while others are noncustodial parents who support children in their extended family as grandparents or uncles.

Whats more, Stephanie Ettinger de Cuba, executive director of Childrens HealthWatch at Boston Medical Center, warns that reducing SNAP benefits could increase health costs in the long run. SNAP acts as important medicine across the lifespan, she said. Food insecurity and hunger are highly correlated with negative health outcomes, such as depression, diabetes, and anemia. One study showed that participation in SNAP was associated with a reduction in health care expenditures by roughly $1,400 per person per year. In Massachusetts, health care costs related to food insecurity and hunger were estimated at $2.4 billion in 2016. Food, in this way, is like preventative medicine or primary care.

The move to curb the SNAP state waiver program is misguided, and ought to be reversed by the next president. Denying help getting food to the poor wont do much to help them find full-time work. More likely, it will have a damaging impact on public health, which ultimately affects us all.

Visit link:
Trumps holiday gift: Cutting off help to the poor - The Boston Globe

GLEN COVE, NY A $5.5-million makeover and expansion is underway at Glen Cove Hospital. The hospital is overhauling its outpatient Family Medicine Center, which was built in the 1970s and is located on the first floor. The practice will be moved to a modernized space on the third floor.

The new, 6,660 square-foot center will provide personalized medical services to patients of all ages, offering primary, prenatal and pediatric care, preventative services, behavioral health and gynecological services to underserved populations and other residents.

Kerri Anne Scanlon, Glen Cove Hospital's executive director, called the center "state-of-the-art." Meanwhile, Barbara Keber, chair of family medicine at the hospital and vice chair of family medicine at Northwell Health, said the new center will not only accommodate more patients, but will create a "welcoming and modern environment." It will also improve clinical care and collaboration, she said.

Here are five things to know about the renovation project.

1. The new center will feature 12 exam rooms, bedside ultrasound machines, a procedure room, laboratory and medication room and modern reception and seating areas.

2. A large, glass enclosed area will be the focal point of the space, offering central views and monitoring of the center. It will also allow clinical team members to huddle before visiting patients in a confidential setting.

3. More than 18,500 patients are expected to be served by the new center, an increase in patient volume of 40 percent.

4. The hospital expects the center will open in late spring.

5. The expansion comes after three years of focused fundraising efforts by community members. To date, the community has raised $3.5 million.

See the article here:
Glen Cove Hospital Renovation And Expansion: 5 Things To Know - Glen Cove, NY Patch

From ancient China to your kitchen, tea has shaped our culture and our brains. Lillian Loescher describes what this could indicate.

That cuppa you have in the morning may be more beneficial to your health than you think. A study recently published in the scientific journal, Aging, describes the positive effects of regular tea consumption on brain structure and touted its protective impacts on age-related decline in brain organization. This comes as no surprise as there have been decades of scientific research about the positive effects of tea consumption on the brain.

Scientist Junhua Li and colleagues showed the first evidence of the positive contribution of tea drinking to brain structure and [their research] suggests a protective effect on age-related decline in brain organization. Junhua Li and colleagues found that those who habitually drank tea had better functional connectivity within the default mode network (DMN) in their brains as compared to those who did not drink tea habitually. The DMN is an interconnected set of structures in the brain between the dorsal medial system and the medial temporal system. These structures are responsible for attention, memory, awareness and spatial navigation as well as higher level thought processes including predicting the future actions of people around you and an ability to reflect on others thought processes and beliefs.

The ability to reflect on others thought processes and beliefs is what psychologists call having a theory of mind. It has been well documented that people on the autism spectrum as well as those with Alzheimers disease have an impaired theory of mind. One large medical review looking at the effect of tea on the prevention of Alzheimers disease found that 8 out of 9 studies concluded that herbal tea had a neuroprotective role and contributed to the prevention of Alzheimers disease. Thus, showing further evidence supporting the positive role of habitual tea consumption on the DMN.

The article produced by Junhua and colleagues has also shown that between the group of older adults who drink tea regularly and the group of older adults who do not drink tea regularly there was higher structural network efficiency found in older adults who had habitual tea drinking. Relative to the non-tea drinking group, the tea drinking group had less topological distance between brain regions and more efficient interregional connectivity.

One of the hallmarks of an aging brain is leftward asymmetry in structural connectivity within the hemispheres of the brain, this can be observed using magnetic resonance imaging (MRI). Scientists have shown that the suppression of hemispheric asymmetry in structural connectivity was associated with tea drinking, tending to be more symmetric in structural connectivity. Specifically, the non-tea drinking group exhibited significantly leftward asymmetryThis hemispheric asymmetry in structural connectivity has been associated with brain ageing.

A separate study looking at the effects of tea on the brain in both humans and animals found that an antioxidant in tea (called catechin) to be extremely beneficial for cognition. As compared to placebo groups, enhancements in memory recognition and working memory were observed following tea consumption over extended periods of time.

Since tea consumption has been shown to be beneficial to brain function, connectivity and symmetry throughout lifetime one must wonder how tea came to be.

The first known monograph of tea was written by LuYu between 760CE and 762CE and is titled: The Classic of Tea. The book describes how to create the perfect cup of tea as well as the therapeutic benefits that tea has. It is said that tea originated in the Yuunan region of China around 4,000 years ago as a medical drink that was believed to represent the harmony and mysterious unity of the universe. Legend has it that tea was discovered by accident by an emperor of China around 2737BC when he was drinking a bowl of boiled water. A breeze hit and some leaves landed in his bowl. Noting the colour change and good taste the emperor was surprised and thus tea became part of the culture. Thousands of years would pass before tea would make its way over to Ireland and the UK.

The first advertisement for tea in the UK appeared in 1658 and officially the tea trade began in 1664. The exact date when tea consumption became popular in Ireland is not known, but the existence of silver teapots from the 1720s suggests that it was well-established by then. For thousands of years across the world tea has been consumed for medicinal and social purposes. The scientific interest in the health benefits of tea will continue to percolate our cultural milieu and perhaps the nature of preventative medicine will be partly shaped by tea consumption.

See the rest here:
Your Brain on Tea - University Observer Online

Researchers at Stanford University have found a way to reliably predict the age of people based on the levels of 373 proteins circulating in their blood. The team created this physiological clock by analysing blood samples from 4263 study participants aged 18 to 95.

The Stanford investigators built their blood plasmaprotein clock by looking at composite levels of proteins within groups of people instead of in individuals, and they say that the resulting formula can usually estimate a persons age to within three years. The team found that a subset of just nine or 10 proteins could form the basis of a very accurate age test, with the assistance of machine learning.

Those whose predicted age was significantly below their real age were remarkably healthy for their age. Nearly two-thirds of the proteins that the researchers found changed with age were significantly more predictive for one sex than for the other.

Overall, the researchers observed that there are three waves of changes in human plasma proteome throughout life occurring around ages 34, 60 and 78. This is because the levels of many proteins remain constant in the human body for a while and then undergo sudden shifts up or down, rather than slowly changing or remaining constant throughout life.

Identifying plasma proteins that promote or antagonise ageing could lead to more targeted and preventative therapies, the researchers suggest. In the future, they say, plasma proteome changes could be identified that predict subjects transitioning to disease. The Stanford team notes that Alzheimers disease is of particular interest because there are currently no blood-based markers for that health condition, and it can produce clinical symptom as much as 20 years after disease onset.

Alireza Delfarah from the University of Southern California, who studies specific mechanisms in ageing, agrees that the new research findings are significant. It is a big step forward in identifying plasma markers of ageing in the future, potentially we can just take plasma samples from people and do a test based on some of these proteins that have been identified, and probably need to be further validated, he says.

However, the Stanford team acknowledges that this work is still in its infancy, and that clinical applications are likely five to 10 years away.

Lizzy Ostler, an expert on the chemistry of human ageing from the University of Brighton in the UK, says the Stanford study is appropriately and rigorously designed, and offers valuable insights into age-related changes. We have known for some time that chronological and biological age are not the same thing, she says. Lifestyle and genetics alter the rate of ageing in the same way that the way you drive your car will change its condition irrespective of mileage.

Broad spectrum interventions that could slow the biological clocks of humans need to be prioritised by global licensing authorities and funders in order to ensure that the field of anti-degenerative medicine comes of age and helps people live healthy lives for longer, Ostler suggests.

Read more:
Blood test picks out proteins that accurately predict age - Chemistry World

Brenna Norman/Reuters Democratic presidential candidate Andrew Yang arrives before he plays basketball with former congressional candidate J.D. Scholten in Ames, Iowa, on Dec. 12, 2019.

Andrew Yang released his health care plan Monday morning, a proposal with elements of Medicare for All, but without the public option plan that even moderate candidates like former Vice President Joe Biden and South Bend, Indiana, Mayor Pete Buttigieg have committed to implementing.

"To be clear, I support the spirit of Medicare for All," Yang said in outlining his plan, before adding, "Swiftly reformatting 18% of our economy and eliminating private insurance for millions of Americans is not a realistic strategy, so we need to provide a new way forward on healthcare for all Americans."

In a statement to ABC News, a Yang campaign spokesperson said, "The U.S. is on track to spend a total of $60 trillion on healthcare between 2022-2031. Andrew Yangs plan will cut about $9.7 trillion over this time period by tackling the root problems in the system, including prescription drug costs, utilizing tele-health, decreasing unnecessary medical services, diminishing billing and insurance related waste, minimizing doctor burnout, improving end of life care, and reducing poverty.

His "A New Way Forward" plan includes pieces already in his competitors' plans, but it differs dramatically from other candidates in several key ways too.

"Yangs proposal does not include provisions targeted at expanding insurance coverage," said Matt Fiedler, a fellow with University of Southern California's nonpartisan Brookings Schaeffer Initiative for Health Policy.

Fiedler pointed to Yang's suggestion that coverage cannot extend to everyone in a practical way, and said that's not likely correct.

"While reducing the underlying cost of care is a meritorious goal, it is also quite feasible to achieve universal coverage even as we continue to work on reducing costs," said Fiedler.

While Yang's six-pronged plan doesn't work to expand the current system, it does attempt to revamp it in a way that weaves in his previous policy pitches.

Just last week, Yang released his plan to lower prescription drug costs. His health care plan builds on some of his earlier promises to hold pharmaceutical companies accountable by directing the Food and Drug Administration and Department of Justice to work together in bringing criminal cases against pharmaceutical execs who use misleading marketing tactics.

Yang also commits to investing in telehealth, information and services given over the phone or internet, noting that the demand for physicians is outpacing the available supply.

His third prong also touches on the demand for doctors, and proposes forgiving their student loans and moving them through a fee-for-service system to a salary system.

He also wants to do more to shield doctors from malpractice lawsuits arguing, "We need to allow doctors to practice medicine that prioritizes their patients health without legal fear in the back of their minds."

Yang's last points focus on preventative care, and putting health care resources into suicide prevention, mental health checkups, handicapped patients and treatment for HIV/AIDS patients.

He closes the plan by explaining how he would minimize lobbyist influence in the health care industry, saying in part, he will refuse to hire anyone who previously worked at a pharmaceutical industry as a lobbyist.

Read the original post:
Yang draws contrasts with rest of field on health care plan - msnNOW

LOS ANGELES (PRWEB) December 11, 2019

Circularity is partnering with Telly Award-Winning Behind the Scenes to provide regular, ongoing, high-quality content from leading experts in a variety of fields with an initial focus on microcirculation science, regenerative medicine, and advanced wound healing and related symptoms. The show reaches 60 million households domestically.

Behind The Scenes with Host Laurence Fishburne is a public television icon that has won numerous awards and delivers precision idea-telling at its best. Circularity is an innovative healthcare organization that is health-bent on their trademarked slogan: Improving Lives by Improving Blood Flow. Their coming together to bring forward the ideas of modern health science on a stellar entertainment platform can only make for riveting content going forward. Viewers will find themselves in a win-win situation.

Watching informative content via this stylized venue will leave viewers feeling quite satisfied with their television watching experience. It is time well spent and information precisely delivered.

A Little More About Circularity

Circularity is concerned with bringing the very best in healthcare innovation to the public. In so doing, they have manufactured a product called DOXYVA. This product has a two-pronged approach to health. First, it can be quite effective in reducing the debilitative effects of many of the diseases that are affecting the world today, such as COPD, diabetes, and cardiovascular illnesses. Secondly, Circularitys DOXYVA can be used in a preventative capacity to improve microcirculation. The concept of microcirculation has far-reaching implications in neurology, oncology, endocrinology, cardiovascular health, respiratory health, dermatology, diabetic wound healing or diabetic wound care and other major fields.

Circularity Healthcare, LLC is the power behind DOXYVA. This noninvasive trans-dermal and circulatory health technology is just the first product to be offered. Circularity is invested in revolutionizing the healthcare space. They plan to do this by creating cutting edge medical products and procedures that are both patient and physician friendly while being effective in minimizing and eradicating diseases.

What Behind The Scenes with Host Laurence Fishburne Will Bring to the Table

Behind The Scenes has been an innovator in bringing information to the forefront in the public television space. The award-winning series features segments on the newest technologies, as well as fresh takes on existing entities, phenomenon, and natural occurrences. The shows website boasts that the television series highlights the evolution of education, medicine, science, technology and industry through inspiring stories.

Aside from the Emmy-winning and Academy Award nominated actor Lawrence Fishburne as host, the program has an award-winning creative development team. Viewers walk away with a rich knowledge of the subject. Viewers may have known about this subject their whole lives, or it may be about something completely new. Viewers learn an evolving aspect of the topic which keeps the perspective fresh.

The dawning of a new age has appeared with this collaboration. Individuals who want to know more about what the health science field is bringing into our hospitals and doctors offices will not be disappointed. In todays world, it is imperative that we are advocates for our own health.

Coming Soon: Miami ReLifes Dr. Steven Gelbard

The first series is with Dr. Steven Gelbard, a nationally-famed authority with his ReLife Miami Institute on stem cells. Dr. Gelbard presents DOXYVAs Nobel Prize-winning science as a regenerative medicine. Dr. Gelbard is involving his direct contacts with top NFL players and other top sports celebrities in the monthly series, along with 2540 top neurosurgeons and other experts working under ReLife.

Imagine having the ability to receive DOXYVA and other innovative treatments and non-invasive procedures for chronic wound care amid the luxury of a five-star hotel. Behind The Scenes guest, Dr. Gelbard, a Tufts School of Medicine educated neurosurgeon, makes it happen right now. Medicine has left the hospital building and has become the proactive choice of the health conscious. We can all look forward to learning more about how to live a healthier and more informed lifestyle from this awe-inspiring episode.

According to Norbert Kiss, President and CEO of Circularity Healthcare, this collaboration is door busting. Mr. Kiss tells us, [We] can offer unprecedented access to this amazing Emmy-winning show called Behind the Scenes with very amazing terms due to our strategic involvement. We welcome any expert.

Laurence Fishburne, host of Behind The Scenes, beckons, Join me as we all discover the endless ways to enjoy the skills and imagination.

Dont miss the evolution. Its being televised. Circularity and Behind The ScenesStay tuned for a mind-fortifying experience!

Circularity Values:

We, at Circularity believe in a long-sought-after goal in health care; people should have access to one health application that solves most of their short and long term health issues without compromising other aspects of their health while doing this quickly, affordably, and without pain.Circularity develops, manufactures and markets advanced technologies that significantly improve quality of life by improving some of the most essential physiological functions in the body.

About Behind The Scenes With Laurence Fishburne

Behind The Scenes is an award-winning program that highlights new stories and innovative concepts through groundbreaking short-form and long-form documentary presentation. The program, which is anchored by a veteran production team with decades of industry experience, is able to effectively communicate the most critical stories to a wide and diverse audience.

Behind The Scenes with Laurence Fishburne, has established an impressive and heralded career, amassing over one-hundred credits across the varied platforms of stage, television and film. Hes well known for major for roles in such films as; John Wick 2, Fantastic 4 Rise of the Silver Surfer, Mission Impossible III, Mystic River, Boyz n the Hood, Whats Love Got to Do With It, and Apocalypse Now. On the small screen, the award-winning and versatile actor played compelling roles in shows such as CSI: Crime Scene Investigation, CSI: Miami, CSI: New York and Hannibal. The Behind The Scenes Actor currently stars as Pops on the hit TV comedy Black-ish.

About Circularity Healthcare, LLC

Circularity Healthcare, LLC, located in Los Angeles, CA is a private biotech and medtech products and services company that designs, makes, markets, sells, distributes and licenses its own patented and patent pending technologies, such as its flagship non-invasive deoxyhemoglobin vasodilator product line, D'OXYVA. One of the main mechanisms underlying D'OXYVA's science received the Nobel Prize for Medicine in 2019. Circularity enters into exclusive agreements with manufacturers to launch products and with large and small clinics and hospitals in order to help them enhance their profits and credit profiles with a wide variety of advanced products and services. In addition, Circularity Healthcare assists in the financing of equipment, working capital and also patient financing at industry-leading terms and speed.

For more information, please visit http://www.circularityhealthcare.com or http://doxyva.com or doctors (Rx only) visit http://wound.doxyva.com and send your general inquiries via the Contact Us page. For specific inquiries contact Circularity Customer Care at info(at)doxyva(dot)com info(at)circularityhealthcare(dot)com or by phone toll free at 1-855-5DOXYVA or at 1-626-240-0956.

Forward-Looking Information

This press release may contain forward-looking information. This includes, or may be based upon, estimates, forecasts and statements as to managements expectations with respect to, among other things, the quality of the products of Circularity Healthcare, LLC, its resources, progress in development, demand, and market outlook for non-invasive transdermal delivery medical devices. Forward-looking information is based on the opinions and estimates of management at the date the information is given and is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those initially projected. These factors include the inherent risks involved in the launch of a new medical device, innovation and market acceptance uncertainties, fluctuating components and other advanced material prices, new federal or state governmental regulations, the possibility of project cost overruns or unanticipated costs and expenses, uncertainties relating to the availability and costs of financing needed in the future and other factors. The forward-looking information contained herein is given as of the date hereof and Circularity Healthcare, LLC assumes no responsibility to update or revise such information to reflect new events or circumstances, except as required by law. Circularity Healthcare, LLC makes no representations or warranties as to the accuracy or completeness of this press release and shall have no liability for any representations (expressed or implied) for any statement made herein, or for any omission from this press release.

Read the original here:
Innovative Collaboration: The Cutting Edge of Medicine Goes Behind The Scenes - PR Web

Doctor visits can be annoying, especially if you have to take several blood samples to test for a handful of common ailments, not to mention to look for something that might be hard to diagnose.But a new study advises that a novel technique could make this whole process much easier.The research and development that has set the tone for advancements in modern medicine are also helping to make medicine and other treatments more efficient across the board.

For example, health researchers now say they have developed a straightforward blood test that could allow physicians to assess a wide range of ailments and health factors from just one blood sample.Scientists at the University of Cambridge and the University of California-San Franciscoin partnership with biotech SomaLogic HQused several blood samples (from a total of approximately 17,000 patients) to scan 5,000 proteins.

The researchers processed this data using statistical analysis as well as machine learning technology to develop predictive models for a variety of common health problems.

Study author Claudia Langenberg, of the University of Cambridge, explains, Proteins circulating in our blood are a manifestation of our genetic make-up as well as many other factors, such as behaviors or the presence of disease, even if not yet diagnosed.

This is why, she further notes, proteins are known to be such effective indicators of both our present and future health states.With this data we are able to better improve clinical prediction of a handful of different diseases.

Reinforcing her statement, SomaLogic CEO Stephen Williams comments, Its remarkable that plasma protein patterns alone can faithfully represent such a wide variety of common and important health issues, and we think that this is just the tip of the iceberg.

Indeed, this is only the beginning for this method of diagnostics.With more in-depth research and scanning of proteins, there is great potential to map fully individualized health assessments for all patients.

Finally, co-lead author Peter Ganz, University of California-San Francisco comments that this new research marks a crucial milestone in the scientific development of personalized preventative medicine.Ganz is a member of SomaLogics Medical Advisory board, but is not compensated for holding the position.

He explains, This proof-of-concept study demonstrates a new paradigm that measurement of blood proteins can accurately deliver health information that spans across numerous medical specialties and that should be actionable for patients and their health care providers.

See the article here:
New Study Says that A Single Blood Test Could Soon Predict Your Future Disease Risk - Jamestown Journal

When I first took a glance at businessman Andrew Yang, I immediately dismissed him as a hyper-leftist. He supported Medicare-for-All, the most radical healthcare plan being proposed by some of the Democratic candidates. But like others in the field, Yang has walked back his support for Medicare-for-All. His newly released healthcare plan is by far the most moderate being proposed by anyone polling over nil. Its more moderate than Pete Buttigiegs Medicare For All Who Wants It. Its more moderate than Joe Bidens Obamacare 2.0. In fact, its the only plan that, if proposed by Democrats and Republicans together, would likely pass with massive bipartisan support if one component was stripped from it.

Dont get me wrong. Im not a Yang supporter. I have issues with other policies hes proposing and would actually enjoy a conversation with him over a couple that make very little sense to me. But I can say this about the candidates proposals: Hes the only one in the field who could appeal to right-leaning Independents and moderate Republicans in the general election. Polls say that person is either Biden or Buttigieg, but heres the catch: When people start taking a closer look at the policy proposals theyve backed themselves into in an attempt to appease the far-left in their party, those policies wont hold up to scrutiny. They are to the left of President Obama and candidate Hillary Clinton. Theyre much further to the left than anything this country has ever seen in the White House.

Biden and Buttigieg only seem moderate because the scale has been so skewed by the Democratic Socialist wing that extreme views seem tame compared to the radicals. Yang, on the other hand, has as his branded position the Freedom Dividend, a concept that has been examined by many conservative economists. Milton Friedman proposed a variation of universal basic income in the form of negative tax rates. Others have said it could work if cuts were made to other avenues of spending. A current Republican lawmaker recently told me off the record that if it could be used to reduce the need for welfare, it could actually work well.

What Yang unveiled today as A New Way Forward for healthcare in America is a six-point plan that makes sense. Id strongly recommend Representative Kevin McCarthy and Senator Mitch McConnell give it a serious look.

Here are the bullet points to his six ideas with my commentary below.

The last two ideas are great. Theres a great risk with the others, at least in a vacuum, because healthcare innovation is driven by profits. This is good and bad, but Yangs proposal doesnt address either. Its good thatpharmaceutical research isprofit-driven because it allows for the generation of more funds that private companies can reinvest into more breakthroughs. The bad part is it puts an emphasis on treatments over cures. Treatments are profitable as theyre ongoing. Cures are inherently not profitable.

To truly address the prescription drug issue, incentives need to be established that take advantage of American ingenuity and resources while keeping DCs hands out of it. There have been a handful of proposals Ive read over the years that would drive innovation while also guiding it towards cures and prevention rather than super-profitable ongoing treatments.

These are no-brainers. The only nitpicking I could do would be to take out the broadband access component. It tastes too much like recently proposed Internet for All schemes that suggest spending huge infrastructure dollars to provide digital access to people who simply dont want it. Nobody moves to the boonies in Montana with the expectation of streaming Netflix. They did so for a reason. Those who have intense medical needs wont be hours from the nearest town. Its a pointless addition to the plan. Otherwise, spot-on.

Conservatives may be scared of the idea of federal regulations and licensing. But the plan does not call for the elimination of state medical requirements and licencing. As long as he allows states to regulate their doctors as they see fit but allows for separate telehealth-only licensing and regulations, it passes the federalism smell-test.

Theres a whole lot to unpack here. Capitation and salary plans can work on a small scale but have never been tested on larger scales. There are many risks, especially if it will be the federal government implementing these changes. Were talking about an ideal system in the long-term that could suffer cataclysm on the road to getting there. Its conspicuous that he uses the words work with and explore in the first two bullet points instead of mandate and implement. Such a move could be great if steady hands over a period of time longer than a president can be in the Oval Office were handling it. Thats a lot to ask of DC, but the spirit of the plan is acceptable.

Frivolous malpractice suits yep. No objections to protecting doctors in this regard.

Fix EHR yep. The system is flawed without any good reason other than nobody has addressed it.

There are several slippery slopes in the last three bullet points. Hes describing getting further involved in the way states handle healthcare for their residents. Its a populist concept that would need to be handled carefully. His last two bullet points would shift the job market tremendously. It would raise the costs of hiring specialists because of higher demand and could cause an imbalance of too many primary care physicians.Such programs would have to belimited and adjusted on the fly as needed.

The first bullet point isnt policy, nor should it be. Doctors will do as doctors will do and Ive never met one who didnt tell me to eat better and exercise.

Id want to learn more about the incentives he proposes in the second bullet point. It seems like a nothingburger (or nothingpomegranate, if you prefer) that could eventually lead back to Michelle Obamas school meal decadence plan.

More funding for food banks is good. Better management of charities to feed the needy would be better.

As for the end-of-life proposals, yes, were at a stage in society when all of these ideas make sense. We are better at keeping people alive than we are at maintaining an acceptable quality-of-life. As long as he doesnt get into assisted suicide, these are all positive changes.

The first seven bullet points on mental health and disabilities are good.

Breaking the TRUVADA patent is dangerous only because it sets a precedent. Yes, its important, but the last thing we need is for pharmaceutical companies to pull back the reins on treatments or prevention options because they believe theyre going to lose profits when the government decrees their patents are void.

Then, theres the abortion component. Remember when I said above that one component would have to be stripped? This is it. Yang needed to include it if he has any chance of winning the nomination, but its a non-starter for millions of Americans, including me.

Covering maternity costs is another populist view that would require a full cost analysis to see if its even possible.

Including vision and dental should not be mandated. Theres already a vibrant and affordable market for coverage. This isnt solving a problem. It just mandates convenience at unnecessary expense. It wont save anyone money and could end up costing more as theprices associated are hidden.

Selling a public option as reducing burden on employers is smart. I dont agree with it as the burden would be transferred to taxpayers, but since Republicans seem to no longer be in the business of repealing Obamacare, this really wouldnt be much of a change from the status quo.

So, the $100 Democracy Dollars incentive is odd, but only because I probably dont understand how it works. Call me obtuse. Everything else in his portion of his plan makes sense and should be extended outside of healthcare.

Lawmakers on both sides of the aisle should take a look at Andrew Yangs plan. Its the only healthcare proposal from a Democrat that isnt ludicrous. Considering what Capitol Hill has done with healthcare (nothing), this is worth a peek.

We are currently forming the American Conservative Movement. If you are interested in learning more, we will be sending out information in a few weeks.

See the article here:
Healthcare2 days ago Andrew Yang's healthcare plan could pass today with bipartisan support - NOQ Report

A new multicentre study will investigate the link between brain inflammation and psychosis, and use artificial intelligence techniques to identify patients that might benefit most from novel treatments.

The study, funded by UKRI Medical Research Council, is led by the Universities of Birmingham and Cambridge. Researchers will examine how and if activated inflammatory cells may act differently in psychosis. For example, how they behave in circulation (blood), or whether they cross into the brain and activate immune defence cells and systems.

It is possible these mechanisms could lead to psychosis, and understanding this link could open up new treatment options that target the bodys immune system.

Existing research has shown that some people with psychosis will also have evidence of an activated inflammatory system before and during the early stages of their condition. There is also evidence that inflammation may be related to mood symptoms such as depression, which are common in psychosis.

Psychosis treatment using anti-inflammatory drugs have led to mixed results, however. This is potentially because they were given to patients with psychosis regardless of whether there was evidence of inflammation.

The PIMS (Psychosis Immune Mechanism Stratified Medicine) study will look more closely at the links between inflammation and psychosis and explore how AI techniques can help identify the patients who would benefit most from anti-inflammatory treatment.

Rachel Upthegrove, Professor of Psychiatry in the University of Birminghams Institute for Mental Health, says: New and more effectively targeted treatments are desperately needed for people with psychosis. Evidence suggests that inflammation may be present before and during the early stages of psychosis in some, but not all young people. Through the PIMS study, we are examining how immune dysfunction could be causally related to some symptoms of psychosis, and use Machine Learning and other AI techniques to identify who might benefit most from novel immune targeted treatments.

Dr Golam Khandakar, in the Behavioural and Clinical Neuroscience Institute at the University of Cambridge, says: Around one third of patients with schizophrenia do not get better with current antipsychotic medications. I am excited about working with colleagues at Birmingham and other universities involved in the PIMS project to try and understand whether in future we could target the immune system as a useful way of treating patients with schizophrenia.

Sathnam Sanghera, The Times journalist and author of The Boy in the Topknot, a family memoir about growing up in Wolverhampton in his Punjabi sikh family and about how he didnt know his father and sister had schizophrenia until he was around 30, commented: People talk quite a lot nowadays about the issue of stigma in relation to mental illness. If someone has psychosis they will have the kind of symptoms youll cross the street to avoid or theyll have the kind of symptoms that will make you scared of someone you love. We need funding for more research and new treatments and thats why this study is so important for people suffering like my father and my sister.

Zaynab Sohawon is a member of the Institute for Mental Healths Youth Advisory Group, a group of young people working with Birmingham researchers to create, shape and challenge research into youth mental health. Shesaid: My story started off with adverse childhood experience which led to my mental health deteriorating. This research will help others like me in achieving early intervention in psychotic illnesses.

See the rest here:
Could AI help develop personalised psychosis therapies? - University of Birmingham

Gene therapy is a way of delivering healthy genes or genetic material to cells in order to treat genetic disorders. The most common way to do this is using adeno-associated viruses (AAVs). The outer part of the virus, called the capsid, is generally retained, but the viral genes are replaced with the therapeutic genes. Attempts have been made to improve the capsid or shell of the virus, but usually fail. George Church and his team at Harvard Medical School with the original researchers at the Karolinska Institute and Lund University in Sweden, have developed a technique to modify the capsid. They have also launched a company, Dyno Therapeutics, to develop the approach.

The groups research, by senior author Tomas Bjrklund, with Lund, was published in PNAS, the Proceedings of the National Academy of Sciences of the United States of America.

The technique allows the researchers to engineer the virus shell to deliver the gene package to the exact cell type in the body they intend to treat. The process leverages computer simulations and modeling with gene and sequencing technology.

Thanks to this technology, we can study millions of new virus variants in cell culture and animal models simultaneously, Bjorklund said. From this, we can subsequently create a computer simulation that constructs the most suitable virus shell for the chosen applicationin this case, the dopamine-producing nerve cells for the treatment of Parkinsons disease.

The technique also dramatically decreases the need for laboratory animals. The millions of variations on the same therapy can be studied in the same individual.

The authors wrote, A challenge with the available synthetic viruses used for the treatment of genetic disorders is that they originate from wild-type viruses. These viruses benefit form infecting as many cells as possible in the body, while therapies should most often target a particular cell type, for example, dopamine neurons in the brain.

Current approaches to finding the most advantageous viruses for gene therapy use random screening, enrichment and, the authors say, serendipity. Their technique is dubbed BRAVE (barcoded rational AAV vector evolution). In BRAVE, each virus displays a peptide derived from a protein. That peptide as a known function on the AAV shell surface and what they call a unique molecular barcode in the packaged genome.

By sequencing the RNA-expressed barcodes, they can map the binding sequences from hundreds of proteins simultaneously. They liken the technique to accelerating evolution from millions of years to just weeks.

Bjorklund said The reason we can do this is that we study each generation of the virus in parallel with all the others in the same nerve cells. Unlike evolution, where only the best suited live on to the next generation, we can also learn what makes the virus work less well through this process. This is crucial when building computer models that interpret all the information.

The study showed the potential for using machine learning for AAV design, although the research fell short of actually designing an improved AAV that could be used in clinical testing. Thats where Dyno Therapeutics comes in, working to improve and develop the technique.

Luk Vandenberghe, director of the Grousbeck Gene Therapy Center at Massachusetts Eye and Ear, told C&EN, Chemical & Engineering News, What theyve done here is truly a remarkable tour de force.

Go here to see the original:
Dyno Therapeutics Launches to Improve Viral Vectors for Gene Therapy - BioSpace

Harvard biologist George Church already needed to apologize for a palling around with Jeffrey Epstein even after the financier pleaded to responsible for preying on minors a decade in the past. Now hes elevating eyebrows once morewith plans for a genetics-based courting app.

In an interview with 60 Minutes, Church stated his expertise would pair people based on the propensity of their genes, when mixed in kids, to remove hereditary ailments. Yuko, in contrast, the app, as described, to the Nazi purpose of cultivating a grasp race: I believed we realized after World War II that we werent going to be doing that, she stated.

The church was a part of the coterie of scientists with whom Epstein ingratiated himself via large donations, and Epstein helped bankroll his lab from 2005 to 2007. Church has admitted he repeatedly met and spoke with Epstein for years after the 2008 plea deal that landed him on the intercourse-offender registry.

Epstein had a twisted take on genetics, internet hosting scientific conferences at which he expressed his want to propagate his personal genome by impregnating as much as 20 girls at a time at his New Mexico ranch, like cattle inventory.

Within the 60 Minutes interview, Church referred to as his ties to Epstein unlucky and added: You do not all the time know your donors in addition to you want to.

However, a lot of the phase was dedicated to Churchs genetic-engineering work at Harvard Medical School, together with the app that might theoretically display out potential mates with the improper DNA.

The geneticist didnt drop the apps to identify, or how far alongside its in improvement. He additionally didnt reply to a request for a remark.

Within the interview, the Church acknowledged the drawbacks of genetic sorting. He suffers from dyslexia, consideration deficit dysfunction, and narcolepsyissues that may render him an incompatible match to many. Yuko stated the choice standards could be a sticking level for Churchs app thought.

See the original post:
A New Genetic Based Dating App Will Soon Arrive in The Market - Science Market News

Surge Cities, our second annual ranking of choice metro statistical areas for planting and growing companies, is ostensibly about places. But it's really about people.

For entrepreneurs, what matters is whom you know--also how many you know, how well you know them, how willing they are to help you, and how far you have to go to meet for coffee.

Startup founders with high local connectedness--defined as quality relationships with about 25 other founders, eight investors, and 10 experts--double the revenue growth of those with low connectedness, says Startup Genome, the research and policy organization that is Inc.'s Surge Cities partner. The best way to develop those relationships is through "centers of gravity--places people can meet and build meaningful connections and continue to create value from them," says Arnobio Morelix, Startup Genome's chief innovation officer.

Now, cities vying for entrepreneurial parity with San Francisco, New York, and Boston are engineering their own centers of gravity. Commonly labeled innovation districts, these urban campuses pack in startups and mature companies alongside accelerators and co-working facilities; universities and medical centers; coffee shops, food trucks, outdoor spaces--you get the picture. The operating principle is density. Ideally, smart, creative people bounce off one another in serendipitous "creative collisions" that produce new ideas, relationships, and ventures.

There are roughly 20 substantive innovation districts in the U.S. and more than 100 on the rise worldwide, according to the Brookings Institution. To get an idea how they're serving entrepreneurs, Inc. interviewed three dozen founders in 10 districts around the country. Although a few cited tax credits as the chief advantage (many innovation districts are in opportunity zones), the vast majority said their locations have helped them attract talent, forge partnerships, find early customers, and learn from peers. More developed districts like the St. Louis Cortex Innovation Community, the Chattanooga Innovation District in Tennessee, and Wake Forest's Innovation Quarter in Winston-Salem, North Carolina, earned more love than smaller districts, but no founders regretted their locations.

"The momentum and collaboration over the past 10 years have been amazing to see," says Heidi Jannenga, co-founder and chief clinical officer of WebPT, which develops office-management software for rehab therapists. WebPT was among the first startups in the PHX Core in Phoenix, which today is home to more than 130 companies and six million square feet of research and academic facilities. Like any relatively new district, PHX Core needs to get denser, says Jannenga, and a few more restaurants and other amenities wouldn't hurt. "But what sets us apart" from places like Silicon Valley, she says, "is the generosity. Everyone here is pulling for one another."

The denser the district, the more likely that even the most prosaic activities--attending a networking event, or just crossing the street to get to one--will yield a new customer or business partner. "In this building, there are drug-discovery startups, a company looking at genetic engineering in agriculture, and another looking at drug-delivery systems," says Edward Weinstein, co-founder and CEO of Canopy Biosciences, located in the St. Louis Cortex. Canopy now sells its research tools to a number of district startups "because we talk to them every day," he says. "My last company was 10 miles away, and for eight years, we never met folks in the startup scene."

Stephen Culp is the co-founder of four businesses and a nonprofit in an art deco building in Chattanooga's Innovation District. One day, he was refueling at nearby coffee roaster Mad Priest when he accidentally smacked into Drew Belz, founder and CEO of Fancy Rhino, a nearby branding and video-editing business. Over Belz's broken mug, conversation ensued. Now Fancy Rhino is working with Delegator, Culp's digital ad agency, on a proposal for a D.C.-based think tank. "The more people run into each other, the more they realize what they have in common," Culp says. "The same is true for companies."

Virtually all entrepreneurs said they'd experienced the kind of informal, peer-to-peer exchanges that provide founders advice and emotional sustenance. That's the collegiality Gabe Cooper missed while launching his first software company in a Phoenix suburb. "We weren't near anyone else doing tech," he says. "So we spent a lot of time flying to Silicon Valley to see other tech entrepreneurs."

Cooper moved to the area that would become the PHX Core in 2012, and two years later launched a second company: donor-management system Virtuous CRM. "Here you can be part of all these conversations--people in the coffee shop are talking about customer acquisition," says Cooper. "One of HubSpot's first employees hangs around here. I can just grab him and say, 'Hey, Dan, how should we comp our sales development reps?' " (That Dan would be HubSpot sales director Dan Tyre.)

This ethos of mutual support is embodied by Venture Caf, a nonprofit that hosts five-hour events every Thursday evening in 10 innovation districts around the world, with more on the way. The events, which attract up to 500 people, are designed to tempt founders from their caves with eclectic programming, product demos, and, most important, conversation with people who may change the course of their companies.

Beyond serendipitous interactions, the other universally cited benefit of innovation districts is access to talent. Every firm we interviewed said the amenities and ambiance in these collaborative cores can make recruiting a breeze.

"There are new buildings. A beautiful park. Food trucks. People riding by on bikes and electric scooters," says Brian Platz, co-founder of Fluree, which makes a blockchain-based data-management platform. The startup, Platz's seventh, is based in the Wake Forest Innovation Quarter, a district of more than 170 companies, built around the old R.J. Reynolds Tobacco manufacturing site. "There is so much more creative energy here," he says. "It allows people to imagine themselves hanging out and living here."

As co-founder of a St. Louis design and management consultancy in 2013, Sean Walsh learned that large companies like Monsanto needed outsourced teams of creative, energetic people for software and A.I. projects. Trouble was, he was located in a nondescript, suburban office park, where creative, energetic people didn't want to be caught dead. "I said to my co-founders, 'We're going to start a new company from scratch in the Cortex, because that's where innovative people want to be,' " Walsh says. In 2016, he launched this new company, 1904Labs, in the innovation district, and now it has 85 employees.

Many innovation districts are developed in conjunction with universities or academic medical centers, which act like a virtuous ozone layer, trapping talent and intellectual property so they can't escape the neighborhood. That means abundant interns, but also chances to expand the workforce through collaboration and recruitment. In the Wake Forest district, Jennifer Byrne helped develop a master's program in clinical research at Wake Forest University that she expects to someday supply employees for Javara Research, her platform for improving patient enrollment in clinical trials.

The new Providence Innovation & Design District, in Rhode Island, boasts an unusual variety of academic institutions, including Brown, Johnson & Wales, and the Rhode Island School of Design. "I can hit all of them from here with a baseball," says Adam Alpert, co-founder and CEO of Pangea.app, a platform for matching companies with college students. "I have a little foldable table, and if I have two hours free, I will walk over there and talk with students and hand out stickers." Alpert recently landed a new head of design this way.

One premise of innovation districts is that startup clusters--particularly specialized ones, like autonomous vehicles in Pittsburgh and agtech in St. Louis--may lure investors to open offices there, or at least to visit. The University City Science Center, a 55-year-old urban research park at the heart of what is now uCity Square in Philadelphia, nurtures many of the district's most promising life-science and technology companies. That includes hosting office hours for regional investors to meet with startups. Nyron Burke, founder and CEO of Lithero, which uses A.I. to ensure the legal compliance of life-science-product marketing, raised $100,000 just by walking into a session with Philadelphia-based investor Ben Franklin Technology Partners. "The Science Center is doing the Lord's work," says Burke. But it's not enough, he adds. "Entrepreneurs leave Philadelphia, because it is hard to raise money here."

The money may come to more innovation districts if they produce large exits.In uCity Square, the big dog leading the pack is Spark Therapeutics, a gene-therapy company that Philly native Jeffrey Marrazzo co-founded in 2013 with support from the Children's Hospital of Philadelphia. Today, Spark employs more than 440 people and occupies 200,000 square feet across five buildings in the district. Currently, Marrazzo is awaiting government approval of a $4.8 billion acquisition by Swiss pharmaceuticals giant Roche. It would be the city's biggest-ever VC-backed exit.

Such exits are "hugely important" for entrepreneurial ecosystems like innovation districts, says Startup Genome's Morelix. He calls them "triggers," because they attract resources and also deepen the pockets of early hires, who often go on to invest locally.

In the past, Marrazzo says, startups based on intellectual property from Philadelphia's academic institutions "inevitably moved outside to the suburbs or, more often, licensed out their IP and re-formed in another city, like Boston or San Francisco." Marrazzo kept Spark in the innovation district to buck that trend. Lately, he says, more VCs have reached out to him about the area.

"San Francisco funds and Boston funds are coming here on a regular, scheduled basis," Marrazzo says. "With further success, maybe they'll want to open offices here, too."

From the Winter 2019/2020 issue of Inc. Magazine

See more here:
Want to Make Your City a Startup Hub? You'll Need to Befriend 25 Founders, 8 Investors, and 10 Experts First - Inc.

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, is hosting an R&D Day today beginning at 8am Eastern Time. During the event, Sangamo executives and scientists plan to provide updates across the Companys clinical and preclinical pipeline, as well as an overview of manufacturing capabilities to support clinical and commercial supply. A live webcast link will be available on the Events and Presentations page of the Sangamo website

The talent, R&D capabilities, manufacturing expertise, and operations infrastructure we have brought to Sangamo have enabled us to advance a genomic medicine pipeline that spans multiple therapeutic areas and now also extends into late-stage development, said Sandy Macrae, CEO of Sangamo. As we make progress in clinical development, we gain insights into the use of our technology and are applying those insights as we advance new programs, such as the gene therapy for PKU and the genome regulation candidates for CNS diseases we are announcing today.

Macrae continued: We will continue to pursue a dual approach of retaining certain programs for our proprietary pipeline while also establishing pharmaceutical partnerships to gain access to therapeutic area expertise and financial, operational, and commercial resources. Strategic collaborations will be a particularly important consideration as we advance programs for diseases affecting large patient populations.

R&D Day updates on clinical and preclinical pipeline programs:

Gene therapy product candidates for hemophilia A, Fabry disease, and PKU

SB-525 is a gene therapy product candidate for hemophilia A being developed by Sangamo and Pfizer under a global development and commercialization collaboration agreement. The transfer of the SB-525 IND to Pfizer is substantially completed. Pfizer is advancing SB-525 into a Phase 3 registrational study in 2020 and has recently begun enrolling patients into a Phase 3 lead-in study.

At R&D Day, Sangamo executives are presenting data from the SB-525 program which were recently announced at the American Society of Hematology (ASH) annual meeting.

The cassette engineering, AAV engineering and manufacturing expertise which Sangamo used in the development of SB-525 are also being applied to the ST-920 Fabry disease program, which is being evaluated in a Phase 1/2 clinical trial, as well as to the newly announced ST-101 gene therapy program for PKU, which is being evaluated in preclinical studies with a planned IND submission in 2021.

Engineered ex vivo cell therapy candidates for beta thalassemia, kidney transplantation, and preclinical research in multiple sclerosis (MS)

Sangamo is providing an overview of the Companys diversified cell therapy pipeline this morning. Cell therapy incorporates Sangamos experience and core strengths, including cell culture and engineering, gene editing, and AAV manufacturing. At R&D Day, Sangamo scientists today are reviewing the early data presented this month at ASH from the ST-400 beta thalassemia ex vivo gene-edited cell therapy program, which is being developed in partnership with Sanofi.

Sangamo is also providing updates on the companys CAR-TREG clinical and preclinical programs. CAR-TREGS are regulatory T cells equipped with a chimeric antigen receptor. Sangamo is the pioneer in CAR-TREGS, which may have the potential to treat inflammatory and autoimmune diseases. TX200 is being evaluated in the STEADFAST study, the first ever clinical trial evaluating a CAR-TREG cell therapy. Tx200 is being developed for the prevention of immune-mediated organ rejection in patients who have received a kidney transplant, a significant unmet medical need. Results from this trial will provide data on safety and proof of mechanism, building a critical understanding of CAR-TREGS in patients, and may provide a gateway to autoimmune indications such as Crohns disease and multiple sclerosis (MS). Sangamo is also presenting preclinical murine data demonstrating that CAR-TREGS accumulate and proliferate in the CNS and reduce a marker of MS.

In vivo genome editing optimization

Clinical data presented earlier this year provided evidence that Sangamo had successfully edited the genome of patients with mucopolysaccharidosis type II (MPS II) but also suggested that the zinc finger nuclease in vivo gene editing reagents were under-dosed using first-generation technology. Sangamo has identified potential improvements that may enhance the potency of in vivo genome editing, including increasing total AAV vector dose, co-packaging both ZFNs in one AAV vector, and engineering second-generation AAVs, ZFNs, and donor transgenes.

Genome regulation pipeline candidates targeting neurodegenerative diseases including Alzheimers and Parkinsons

Sangamo scientists today are presenting data demonstrating that the companys engineered zinc finger protein transcription factors (ZFP-TFs) specifically and powerfully repress key genes involved in brain diseases including Alzheimers, Parkinsons, Huntingtons, ALS, and Prion diseases. Sangamo is advancing its first two genome regulation programs toward clinical development:

Sangamo scientists are also presenting data demonstrating progress in the development of new AAV serotypes for use in CNS diseases.

Manufacturing capabilities and strategy

Sangamo is nearing completion of its buildout of a GMP manufacturing facility at the new Company headquarters in Brisbane, CA. This facility is expected to become operational in 2020 and to provide clinical and commercial scale manufacturing capacity for cell and gene therapy programs. The Company has also initiated the buildout of a cell therapy manufacturing facility in Valbonne, France. Sangamos manufacturing strategy includes in-house capabilities as well as the use of contract manufacturing organizations, including a long-established relationship with Thermo Fisher Scientific for clinical and large-scale commercial AAV manufacturing capacity.

R&D Day webcast

A live webcast of the R&D Day, including audio and slides, will be available on the Events and Presentations page of the Sangamo website today at 8am Eastern Time. A replay of the event will be archived on the website.

About Sangamo Therapeutics

Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients lives using gene therapy, ex vivo gene-edited cell therapy, and in vivo genome editing and gene regulation. For more information about Sangamo, visit http://www.sangamo.com.

Sangamo Forward Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of United States securities law. These forward-looking statements include, but are not limited to, the therapeutic potential of Sangamos product candidates; the design of clinical trials and expected timing for milestones, such as enrollment and presentation of data, the expected timing of release of additional data, plans to initiate additional studies for product candidates and timing and design of these studies; the expected benefits of Sangamos collaborations; the anticipated capabilities of Sangamos technologies; the research and development of novel gene-based therapies and the application of Sangamos ZFP technology platform to specific human diseases; successful manufacturing of Sangamos product candidates; the potential of Sangamos genome editing technology to safely treat genetic diseases; the potential for ZFNs to be effectively designed to treat diseases through genome editing; the potential for cell therapies to effectively treat diseases; and other statements that are not historical fact. These statements are based upon Sangamos current expectations and speak only as of the date hereof. Sangamos actual results may differ materially and adversely from those expressed in any forward-looking statements. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to dependence on the success of clinical trials; the uncertain regulatory approval process; the costly research and development process, including the uncertain timing of clinical trials; whether interim, preliminary or initial data from ongoing clinical trials will be representative of the final results from such clinical trials; whether the final results from ongoing clinical trials will validate and support the safety and efficacy of product candidates; the risk that clinical trial data are subject to differing interpretations by regulatory authorities; Sangamos limited experience in conducting later stage clinical trials and the potential inability of Sangamo and its partners to advance product candidates into registrational studies; Sangamos reliance on itself, partners and other third-parties to meet clinical and manufacturing obligations; Sangamos ability to maintain strategic partnerships; competing drugs and product candidates that may be superior to Sangamos product candidates; and the potential for technological developments by Sangamo's competitors that will obviate Sangamo's gene therapy technology. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in Sangamos operations. This presentation concerns investigational drugs that are under preclinical and/or clinical investigation and which have not yet been approved for marketing by any regulatory agency. They are currently limited to investigational use, and no representations are made as to their safety or effectiveness for the purposes for which they are being investigated. Any discussions of safety or efficacy are only in reference to the specific results presented here and may not be indicative of an ultimate finding of safety or efficacy by regulatory agencies. These risks and uncertainties are described more fully in Sangamo's Annual Report on Form 10-K for the year ended December 31, 2018 as filed with the Securities and Exchange Commission on March 1, 2019 and Sangamo's Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 that it filed on or about November 6, 2019. Except as required by law, we assume no obligation, and we disclaim any intent, to update these statements to reflect actual results.

Read more:
Sangamo Highlights Advancements in Genomic Medicine Pipeline and Expanded R&D and Manufacturing Capabilities at R&D Day - Business Wire

XconomySan Diego

Nearly nine years ago Jeanne Loring and her colleagues at Scripps Research debuted a test that leveraged advances in genomics and data science to determine, without testing in animals, whether human stem cells were pluripotent, or able to become any type of cell in the body.

Being able to prove that has become increasingly important as scientists look to induced pluripotent stem cells (iPSCs)mature, specialized cells that have been reprogrammed as immature cells, regaining the capability of becoming any type of cellas material for new regenerative medicines.

Now Loring and Andres Bratt-Leal, who joined her lab in 2012 as a post-doctoral researcher, have founded a biotech that combines stem cell biology and genomics know-how to advance a potential cell therapy for Parkinsons disease.

The startup announced Thursday it raised a seed round of $6.5 million to support its work. Aspens lead drug candidate, which is in preclinical testing, is intended to replace neurons in the brains of people with the disease, which causes those cells to become damaged or die.

When people with Parkinsons disease lose neurons, they also lose a chemical messenger the cells produce, called dopamine. Without dopamine, communication between nerve cells falters, which leads to the debilitating motor problems that characterize the disease. Existing Parkinsons drugs aim to alter dopamine levels. Aspen, however, wants to fix the upstream problem that leads to those lowered levels by reconstructing patients damaged neural networks.

The cell therapy would involve harvesting patients own living cells through a skin biopsy, reprogramming them to immature cells, or iPSCs, then further engineering them to become predisposed to mature into neurons. Once enough of those cells have been grown in the lab, those neuron precursor cells would be delivered directly to the brain.

Using a patients own cells avoids the dangerous immune system reactions that can occur when donor cells are used in such therapies, and obviates the need for immunosuppression drugs. Two cell therapies that use genetic engineering have been approved by the FDA, both of which take and tweak patients T cells into treatments for cancer. Stem cell transplants have been used to treat some cancers.

Aspen worked to ensure the company could ably manufacture a so-called autologous replacement cell therapy, or one from a patients one cells, by improving the process of differentiating iPSCs into dopamine neurons, Loring says. And the group developed another predictive genomic-based test, similar to the effort Loring spearheaded nearly a decade ago to determine whether cells were pluripotent, that can detect which iPSCs are destined to become neurons.

(Bratt-Leal) put his biological engineering expertise into coming up with a way that was reproducible, that we would get the same cells no matter who we got the original cells from, she says.

The company plans to test the therapy in patients that they determine, through genomic testing, have the most common form of Parkinsons, which is referred to as sporadic and arises without a clear genetic predisposition. It also has a second treatment in the works that it intends to develop for patients with familial forms of the disease, and uses a gene editing toolyet to be selectedto alter their stem cells during the reprogramming process.

Howard Federoff, who was most recently vice chancellor for health affairs and CEO of the UC Irvine Health system, is Aspens CEO. Federoff says he has come to believe that Parkinsons patients need more than just to stabilize their disease They need to turn the clock back.

Many companies are working on drugs to treat Parkinsons, but most are meant to manage symptoms rather than reverse the disease. Levodopa, which supplants missing dopamine, is used widely, but it can cause side effects, including involuntary movement called dyskinesia; and, as the disease progresses, the drug eventually stops working between doses.

Aspen claims it is the only company working toward an autologous neuron replacement. The company, however, will need to raise a Series A round to move its drug candidates through Phase 2 proof-of-concept trials, Loring says.

The company raised its seed round from a group of investors including Domain Associates, Alexandria Venture Investments, Arch Venture Partners, Axon Ventures, OrbiMed, and Section 32. Initially, it was financed through grants from Summit for Stem Cell, a San Diego-based nonprofit.

Sarah de Crescenzo is an Xconomy editor based in San Diego. You can reach her at sdecrescenzo@xconomy.com.

Continued here:
Aspen Neuro Bags $6.5M to Test Parkinson's Disease Stem Cell Therapy - Xconomy

And speaking of both Disney+ and Star Wars, that combination resulted in the most-watched show of any of the streaming services, The Mandalorian. Oh, and then there's Baby Yoda. Which brings us to the most recent reason Iger is having a good year: he was just named Time's Businessperson of the Year. Make no mistake, Baby Yoda is a perfect example of why that honorwas well-earned.

The Time article tells a brief story of how Iger knew immediately Baby Yoda would be an enormous hit with fans. For Disney, by the way, enormous hits are the standard operating procedure. In fact, the entire strategy looks something like this:

Create a story with adorable characters. Mass market both the story and the characters. Manufacture merchandise featuring adorable characters. Stuff more cash than you can imagine into the bank account.

In the case of Baby Yoda, Iger not only knew that the character would lead to huge sales, but also that the best play was radio silence until after the first episode of The Mandalorian streamed, so as not to spoil the reveal.

He wasright, of course.

Look, regardless of what you think of the mysterious green alien that has become the star of the Disney+ service and the mascot of the internet, there's really no arguing that from a business standpoint, Baby Yoda is brilliant. And it's a great lesson for entrepreneurs.

Here's why: Bob Iger isn't a storyteller--at least not in the classic sense of someonewho writesa scriptor directs a film. That isn't his role.But he has one thing that might be even more important--a sense of how stories connect with audiences. I'm not sure anyone would disagree that Iger knows his audience, and knows how to steward both the Disney brand as a whole, as well as the individual stories within it (Star Wars, Marvel, etc.)to make sure they resonate with that audience.

But Iger didn't create The Mandalorian or its most famous character. He didn't invent streaming video. He didn't dream upthe Star Wars universe. He isn't a comic book illustrator.

The puzzle that makes up Disney has an extraordinary number of pieces, none of which originated with its CEO. Instead, Iger's job is to see how all of those pieces fit together, and sell the resulting picture tothe rest of us.

And, just because you aren't running the world's largest media and entertainment company, doesn't mean that you don't have a story to tell.And, it doesn't mean you can't learn from what made Bob Iger so successful this year.

In most of the areas Disney competes, it is the apex predator. It's the biggest player in theme parks. It's the biggest licensor of toy characters. It's the biggest sports broadcaster. It's the biggest animation studio. It's the biggest family-friendlymovie producer.

It is not the biggeststreaming video service. It isn't the biggest player--Netflix has over 150 million subscribers--a number that dwarfs Disney+. But it made a huge bet that owning its own platform to stream its own library of content would pay off in a big way.

So far it has. And the lesson here is that when you align your story with your audience, you will win.

That's one of the most important qualities in any marketer, but also in every entrepreneur. Your primary job, at least at first,is to figure out how to tell the story of your brand, and then tell it to the right audience.

And you don't even need Baby Yoda for that--but it can'thurt.

The opinions expressed here by Inc.com columnists are their own, not those of Inc.com.

Visit link:
Disney's Bob Iger Was Just Named Time's Businessperson of the Year and Baby Yoda Is Exactly the Reason Why - Inc.

Christmas Is A Season Not Only Of Rejoicing But Of Reflection. Avail Up To 40% Off On All Our Qualitative Research Reports. Be the Santa of Your Happy Business!

Worldwide Genetic Engineering Drug Market is a report created by Global Marketers.Biz. The Genetic Engineering Drug market research report is segmented on the basis of device, technology, application, and region. Primary and secondary research efforts were invested to arrive at intelligent conclusions presented in the report on the global target market. Findings and conclusions of the research were verified by experts from the industry before including it in the report.

It is a compilation of analytical study based on historical records, current, and upcoming statistics and future developments of the Genetic Engineering Drug Industry. Based on the study, Global Marketers.Biz predicts that the market will see a comparable and steady CAGR growth.

Genetic Engineering Drug Market Segmentation By Type, Applications & Regions

Fill Out Details To Receive FREE Sample Report Copy Here: https://www.globalmarketers.biz/report/life-sciences/global-genetic-engineering-drug-industry-market-research-report/4570 #request_sample

The report covers a forecast and an analysis of the Genetic Engineering Drug Market on a global and regional level. The ancient data is given from 2013-2018 and the estimate period is from 2019-2023 based on revenue (USD Billion). The Genetic Engineering Drug market was estimated at XX Million US$ in 2019 and is probable to grasp XX Million US$ by 2023, at a CAGR of XX% throughout 2019-2023.

The study is also compiled on the basis of the latest and upcoming innovations, opportunities and trends. In addition to SWOT analysis, the report also contains a detailed market analysis outlining every major player in the process.

Avail Up To 40% Off On All Our Qualitative Research Reports.

Inquire Before Buying Or Ask For More Details: https://www.globalmarketers.biz/report/life-sciences/global-genetic-engineering-drug-industry-market-research-report/4570 #inquiry_before_buying

The Report Answers the key Questions related to the Genetic Engineering Drug Market:

What are the important trends and dynamics?

Where will most development take place in the long term?

What does the competitive landscape look like?

What the openings are yet to come?

TOC of Genetic Engineering Drug Market Report Includes:

1. Industry Overview of Genetic Engineering Drug

2. Industry Chain Analysis of Genetic Engineering Drug

3. Manufacturing Technology of Genetic Engineering Drug

4.Major Manufacturers Analysis of Genetic Engineering Drug

5. Global Productions, Revenue and Price Analysis of Genetic Engineering Drug by Regions, Creators, Types and Applications

6. Global and Foremost Regions Capacity, Production, Revenue and Growth Rate of Genetic Engineering Drug 2013-2019.

7. Consumption Volumes, Consumption Value, Import, Export and Trade Price Study of Genetic Engineering Drug by Regions

8. Gross and Gross Margin Examination of Genetic Engineering Drug

9. Marketing Traders or Distributor Examination of Genetic Engineering Drug

10. Worldwide Impacts on Genetic Engineering Drug Industry,

11. Development Trend Analysis of Genetic Engineering Drug

12. Contact information of Genetic Engineering Drug

13. New Project Investment Feasibility Analysis of Genetic Engineering Drug

14. Conclusion of the Global Genetic Engineering Drug Industry 2019 Market Research Report

Continued

Finally, the feasibility of new investment projects is assessed, and overall research conclusions are offered.

Customization Service of the Report:

Global Marketers.biz provides customization of reports as per your need. The report can be altered to meet your requirements. Contact our sales team, who will guarantee you to get a report that suits your needs.

Please get in touch with our sales squad (Alex@globalmarketers.biz).

For more relevant information visit https://www.globalmarketers.biz/

Avail Up To 40% Off On All Our Qualitative Research Reports.

Request for more detailed information (TOC and Sample): https://www.globalmarketers.biz/report/life-sciences/global-genetic-engineering-drug-industry-market-research-report/4570 #table_of_contents

Read the rest here:
Global Genetic Engineering Drug Market | 2018-2023 Growth Analysis, Business Opportunities, Sales, Revenue, Gross Margin, Advance Technology and...

Inspiring coaches go for quantity, not quality, of ideas to build a culture of innovation and ownership. They make ideas-;lots of them-;part of everyones job. They use clarifying questions to determine if and how to best implement the ideas.

Ask your team for the kinds of ideas you need. You may have a focus area for that week, month, or quarter. A good place to start is with the eight areas of waste.

Transport-;Moving people, products, and information

Inventory-;Storing parts, pieces, and documentation ahead of requirements

Motion-;Bending, turning, reaching, lifting

Waiting-;For parts, information, instructions, equipment

Overproduction-;Making more than is immediately required

Over-processing-;Tighter tolerances or higher- grade materials than are needed

Defects-;Rework, scrap, incorrect/incomplete information

Skills-;Underutilizing capabilities, delegating tasks with inadequate training

Involve your team in addressing these areas of waste and other opportunities for improvement to enlist their ownership in the solution.

One of mylong-standing clients, Jeff Jensen, manages a portfolio of successful companies. Jeff has shared a favorite quote from his late father, Ron Jensen, who was an innovative and inspiring leader. He liked to say, The biggest room in the world is the room for improvement.

This metaphorical room for improvement can be your business, your teams processes, your teams skills, and most importantly, your own leadership.

The opinions expressed here by Inc.com columnists are their own, not those of Inc.com.

View post:
8 Ways to Reduce Waste - Inc.